Table 4 Interaction between PDA (definition A) and study secondary outcomes.
Outcome | Subgroups | Late Surfactant N = 252 | Control N = 259 | Adjusted odds ratio* (95% CI) | P value for interaction |
|---|---|---|---|---|---|
Persistent Pulmonary Morbidity | PDA | 27/75 (36.0%) | 35/76 (46.1%) | 0.84 (0.57–1.25) | 0.21 |
No PDA | 47/133 (35.3%) | 44/142 (31.0%) | 1.00 (0.72–1.40) | ||
No Pulmonary Morbidity | PDA | 29/75 (29.3%) | 16/85 (18.2%) | 1.43 (0.82–2.50) | 0.43 |
No PDA | 37/135 (27.4%) | 35/144 (24.3%) | 1.14 (0.78–1.68) | ||
BPD at 36 weeks’ PMA | PDA | 61/89 (68.5%) | 65/94 (69.1%) | 0.99 (0.82–1.2) | 0.69 |
No PDA | 93/162 (57.4%) | 89/164 (54.3%) | 1.06 (0.87–1.28) | ||
BPD at 40 weeks’ PMA | PDA | 33/89 (37.1%) | 42/93 (45.2%) | 0.82 (0.58–1.17) | 0.46 |
No PDA | 49/162 (30.2%) | 51/163 (31.3%) | 0.97 (0.7–1.34) | ||
Death before 36 weeks’ PMA | PDA | 3/89 (3.4%) | 7/94 (7.4%) | 0.45 (0.12–1.7) | 0.29 |
No PDA | 15/162 (9.3%) | 15/164 (9.1%) | 1.01 (0.51–2) | ||
Death before 40 weeks’ PMA | PDA | 5/89 (5.6%) | 8/93 (8.6%) | 0.65 (0.22–1.92) | 0.44 |
No PDA | 16/162 (9.9%) | 15/163 (9.2%) | 1.07 (0.55–2.1) | ||
Grade 2 or 3 BPD, or death before 36 weeks’ PMA | PDA | 31/89 (34.8%) | 38/94 (40.4%) | 0.86 (0.59–1.25) | 0.27 |
No PDA | 56/162 (34.6%) | 50/164 (30.5%) | 1.13 (0.83–1.55) | ||
Grade 3 BPD, or death before 36 weeks’ PMA | PDA | 12/89 (13.5%) | 12/94 (12.8%) | 1.06 (0.5–2.23) | 0.71 |
No PDA | 26/162 (16%) | 21/164 (12.8%) | 1.25 (0.74–2.13) | ||
Duration Mechanical Ventilation ≥37 days (Median) | PDA | 61/89 (68.5%) | 56/95 (58.9%) | 1.16 (0.93–1.45) | 0.32 |
No PDA | 70/163 (42.9%) | 69/164 (42.1%) | 1.02 (0.79–1.31) | ||
Home Respiratory Support Post-Discharge | PDA | 33/74 (44.6%) | 47/83 (56.6%) | 0.79 (0.57–1.08) | 0.69 |
No PDA | 47/134 (35.1%) | 71/140 (50.7%) | 0.69 (0.52–0.92) | ||
Total NICU Days ≥106 days (Median) | PDA | 51/89 (57.3%) | 51/95 (53.7%) | 1.07 (0.82–1.38) | 0.67 |
No PDA | 77/163 (47.2%) | 78/164 (47.6%) | 0.99 (0.79–1.25) |
